H
Hepagene Therapeutics
Chronic Hepatitis B Infection (HBV)
About Hepagene Therapeutics
Hepagene Therapeutics, Inc. is a clinical-stage drug discovery and development company focused on creating innovative medicines to combat liver diseases and other life-threatening conditions. The company primarily targets non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection (HBV), and Hepatocellular Carcinoma. Hepagene operates in the biopharmaceutical market, serving patients who suffer from these severe liver conditions. The business model revolves around the discovery, development, and delivery of new therapeutic drugs, with revenue generated through the successful commercialization of these treatments. The company recently announced the dosing of the first healthy subject in a Phase I study of HPG1860, a promising drug candidate for NASH.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2021 | $40M | $160M | Oceanpine Capital · Apricot Capital · Loyal Valley Capital | ↗ |
Growth signals
Latest recorded traffic for Hepagene Therapeutics is 50 monthly website visits, down 92.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hepagene Therapeutics in the Pudong ecosystem
The Hepagene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Loyal Valley Capital
Oceanpine Capital
Apricot Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hepagene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hepagene Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









